NeoGenomics cuts FY25 revenue view to $720M-$726 from $747M-$759M

Consensus $744.61M. Cuts FY25 adjusted EBITDA view to $41M-$44M from $55M-$58M. “Looking ahead, we believe Neo will continue to perform as a double-digit revenue growth company, poised to capture additional market share,” continued Zook. “We are enhancing our R&D efforts to develop new therapy selection and next-gen MRD products. We are also preparing for the commercial launch of PanTracer Liquid Biopsy, continuing to grow our sales team, increasing efficiencies, and pursuing partnerships through business development efforts that will enhance our portfolio and strengthen our community channel. We are confident that Neo will deliver long-term value for our customers, patients, and shareholders.”